These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16370374)

  • 1. Analysis of drug-induced effect patterns to link structure and side effects of medicines.
    Fliri AF; Loging WT; Thadeio PF; Volkmann RA
    Nat Chem Biol; 2005 Dec; 1(7):389-97. PubMed ID: 16370374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response.
    Fliri AF; Loging WT; Thadeio PF; Volkmann RA
    J Med Chem; 2005 Nov; 48(22):6918-25. PubMed ID: 16250650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of system structure-function relationships.
    Fliri AF; Loging WT; Volkmann RA
    ChemMedChem; 2007 Dec; 2(12):1774-82. PubMed ID: 17952882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug effects viewed from a signal transduction network perspective.
    Fliri AF; Loging WT; Volkmann RA
    J Med Chem; 2009 Dec; 52(24):8038-46. PubMed ID: 19891439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
    Cavero I
    Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological spectra analysis: Linking biological activity profiles to molecular structure.
    Fliri AF; Loging WT; Thadeio PF; Volkmann RA
    Proc Natl Acad Sci U S A; 2005 Jan; 102(2):261-6. PubMed ID: 15625110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of adverse drug reactions using decision tree modeling.
    Hammann F; Gutmann H; Vogt N; Helma C; Drewe J
    Clin Pharmacol Ther; 2010 Jul; 88(1):52-9. PubMed ID: 20220749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core trees and consensus fragment sequences for molecular representation and similarity analysis.
    Lounkine E; Bajorath J
    J Chem Inf Model; 2008 Jun; 48(6):1161-6. PubMed ID: 18491888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.
    Deaton AM; Fan F; Zhang W; Nguyen PA; Ward LD; Nioi P
    Toxicol Sci; 2019 Feb; 167(2):593-603. PubMed ID: 30346593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating between drugs and nondrugs by prediction of activity spectra for substances (PASS).
    Anzali S; Barnickel G; Cezanne B; Krug M; Filimonov D; Poroikov V
    J Med Chem; 2001 Jul; 44(15):2432-7. PubMed ID: 11448225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Random molecular fragment methods in computational medicinal chemistry.
    Lounkine E; Batista J; Bajorath J
    Curr Med Chem; 2008; 15(21):2108-21. PubMed ID: 18781938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug target identification using side-effect similarity.
    Campillos M; Kuhn M; Gavin AC; Jensen LJ; Bork P
    Science; 2008 Jul; 321(5886):263-6. PubMed ID: 18621671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection criteria for drug-like compounds.
    Muegge I
    Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathway analysis for design of promiscuous drugs and selective drug mixtures.
    Sivachenko A; Kalinin A; Yuryev A
    Curr Drug Discov Technol; 2006 Dec; 3(4):269-77. PubMed ID: 17430103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New technologies in drug metabolism and toxicity screening: organ-to-organ interaction.
    Bhushan A; Martucci NJ; Usta OB; Yarmush ML
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):475-7. PubMed ID: 26940609
    [No Abstract]   [Full Text] [Related]  

  • 19. Secondary pharmacology: screening and interpretation of off-target activities - focus on translation.
    Whitebread S; Dumotier B; Armstrong D; Fekete A; Chen S; Hartmann A; Muller PY; Urban L
    Drug Discov Today; 2016 Aug; 21(8):1232-42. PubMed ID: 27140035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.